464 related articles for article (PubMed ID: 29514797)
1. CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells.
Pahl JHW; Koch J; Götz JJ; Arnold A; Reusch U; Gantke T; Rajkovic E; Treder M; Cerwenka A
Cancer Immunol Res; 2018 May; 6(5):517-527. PubMed ID: 29514797
[TBL] [Abstract][Full Text] [Related]
2. Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30
Kerbauy LN; Marin ND; Kaplan M; Banerjee PP; Berrien-Elliott MM; Becker-Hapak M; Basar R; Foster M; Garcia Melo L; Neal CC; McClain E; Daher M; Nunez Cortes AK; Desai S; Inng Lim FW; Mendt MC; Schappe T; Li L; Shaim H; Shanley M; Ensley EL; Uprety N; Wong P; Liu E; Ang SO; Cai R; Nandivada V; Mohanty V; Miao Q; Shen Y; Baran N; Fowlkes NW; Chen K; Muniz-Feliciano L; Champlin RE; Nieto YL; Koch J; Treder M; Fischer W; Okamoto OK; Shpall EJ; Fehniger TA; Rezvani K
Clin Cancer Res; 2021 Jul; 27(13):3744-3756. PubMed ID: 33986022
[TBL] [Abstract][Full Text] [Related]
3. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.
Reusch U; Burkhardt C; Fucek I; Le Gall F; Le Gall M; Hoffmann K; Knackmuss SH; Kiprijanov S; Little M; Zhukovsky EA
MAbs; 2014; 6(3):728-39. PubMed ID: 24670809
[TBL] [Abstract][Full Text] [Related]
4. Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.
Gantke T; Weichel M; Herbrecht C; Reusch U; Ellwanger K; Fucek I; Eser M; Müller T; Griep R; Molkenthin V; Zhukovsky EA; Treder M
Protein Eng Des Sel; 2017 Sep; 30(9):673-684. PubMed ID: 28981915
[TBL] [Abstract][Full Text] [Related]
5. Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells.
Mishra HK; Pore N; Michelotti EF; Walcheck B
Cancer Immunol Immunother; 2018 Sep; 67(9):1407-1416. PubMed ID: 29978334
[TBL] [Abstract][Full Text] [Related]
6. IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.
Sim GC; Liu C; Wang E; Liu H; Creasy C; Dai Z; Overwijk WW; Roszik J; Marincola F; Hwu P; Grimm E; Radvanyi L
Cancer Immunol Res; 2016 Nov; 4(11):983-994. PubMed ID: 27697858
[TBL] [Abstract][Full Text] [Related]
7. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
Front Immunol; 2018; 9():2873. PubMed ID: 30574146
[TBL] [Abstract][Full Text] [Related]
8. Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity.
Ellwanger K; Reusch U; Fucek I; Wingert S; Ross T; Müller T; Schniegler-Mattox U; Haneke T; Rajkovic E; Koch J; Treder M; Tesar M
MAbs; 2019 Jul; 11(5):899-918. PubMed ID: 31172847
[TBL] [Abstract][Full Text] [Related]
9. NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.
Jaime-Ramirez AC; McMichael E; Kondadasula S; Skinner CC; Mundy-Bosse BL; Luedke E; Jones NB; Mani A; Roda J; Karpa V; Li H; Li J; Elavazhagan S; La Perle KM; Schmitt AC; Lu Y; Zhang X; Pan X; Mao H; Davis M; Jarjoura D; Butchar JP; Poi M; Phelps M; Tridandapani S; Byrd JC; Caligiuri MA; Lee RJ; Carson WE
Cancer Immunol Res; 2016 Apr; 4(4):323-336. PubMed ID: 26865456
[TBL] [Abstract][Full Text] [Related]
10. Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies.
Zhao Y; Li Y; Wu X; Li L; Liu J; Wang Y; Liu Y; Li Q; Wang Z
Cancer Biol Ther; 2020; 21(1):72-80. PubMed ID: 31564196
[TBL] [Abstract][Full Text] [Related]
11. Evidence for CD16a-Mediated NK Cell Stimulation in Antibody-Mediated Kidney Transplant Rejection.
Parkes MD; Halloran PF; Hidalgo LG
Transplantation; 2017 Apr; 101(4):e102-e111. PubMed ID: 27906829
[TBL] [Abstract][Full Text] [Related]
12. Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity.
van Hauten PMM; Hooijmaijers L; Vidal-Manrique M; van der Waart AB; Hobo W; Wu J; Blijlevens NMA; Jansen JH; Walcheck B; Schaap NPM; de Jonge PKJD; Dolstra H
Cytotherapy; 2024 Mar; 26(3):252-260. PubMed ID: 38127030
[TBL] [Abstract][Full Text] [Related]
13. Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy.
Wu J; Mishra HK; Walcheck B
J Leukoc Biol; 2019 Jun; 105(6):1297-1303. PubMed ID: 30786043
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.
Rothe A; Sasse S; Topp MS; Eichenauer DA; Hummel H; Reiners KS; Dietlein M; Kuhnert G; Kessler J; Buerkle C; Ravic M; Knackmuss S; Marschner JP; Pogge von Strandmann E; Borchmann P; Engert A
Blood; 2015 Jun; 125(26):4024-31. PubMed ID: 25887777
[TBL] [Abstract][Full Text] [Related]
15. [Effect of various combinations of IL2, IL12 and IL15 on function of human peripheral blood derived NK cells].
Li XH; Ma J; Wu XX; Li M; Wang FF; DA WM; Yu L; Gao CJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):918-23. PubMed ID: 19698229
[TBL] [Abstract][Full Text] [Related]
16. AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.
Wu J; Fu J; Zhang M; Liu D
J Hematol Oncol; 2015 Aug; 8():96. PubMed ID: 26231785
[TBL] [Abstract][Full Text] [Related]
17. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.
Zhu H; Blum RH; Bjordahl R; Gaidarova S; Rogers P; Lee TT; Abujarour R; Bonello GB; Wu J; Tsai PF; Miller JS; Walcheck B; Valamehr B; Kaufman DS
Blood; 2020 Feb; 135(6):399-410. PubMed ID: 31856277
[TBL] [Abstract][Full Text] [Related]
18. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
19. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
[TBL] [Abstract][Full Text] [Related]
20. Identification of high-affinity anti-CD16A allotype-independent human antibody domains.
Li W; Yang H; Dimitrov DS
Exp Mol Pathol; 2016 Oct; 101(2):281-289. PubMed ID: 27712994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
